Gene Therapy for Overactive Bladder: What Research Shows

If you have overactive bladder, you already know the options are limited. Medications help some people but bring side effects. Botox injections work well but wear off every few months. And many patients cycle through treatments without finding one that sticks.

That’s why a new approach getting attention from researchers is worth paying attention to: gene therapy. Instead of blocking signals or paralysing muscle, gene therapy for overactive bladder aims to change how bladder cells behave at a molecular level. The idea is a single injection that could reduce urgency, frequency, and leakage for months or even years.

It’s still experimental. But the data so far, from a randomised clinical trial published in the Journal of Urology in 2025, suggests this approach works and is safe 1. Here’s what we know.

Why Current OAB Treatments Fall Short

Overactive bladder affects roughly 20% of the global population, with women affected more often than men 2. The condition involves involuntary contractions of the detrusor muscle, leading to sudden urgency, frequent urination, and often urge incontinence.

First-line medications fall into two categories: anticholinergics (oxybutynin, solifenacin, tolterodine) and newer beta-3 agonists (mirabegron, vibegron). Anticholinergics reduce bladder contractions but also cause dry mouth, constipation, and blurred vision. More concerning, long-term use has been linked to increased dementia risk in older adults. Beta-3 agonists have fewer cognitive side effects, but they don’t work for everyone.

For patients who don’t respond to pills, the next step is usually Botox (onabotulinumtoxinA) injections into the bladder wall. Botox is effective, with about 60-70% of patients seeing significant improvement. But it requires repeat injections every 6-12 months, and roughly 5-10% of patients develop urinary retention severe enough to need temporary catheterisation.

Sacral neuromodulation (an implanted device that stimulates nerves controlling the bladder) is another option, but it involves surgery and ongoing maintenance.

The pattern is clear: current treatments either don’t last, come with concerning side effects, or require repeated procedures. That gap is exactly what gene therapy is trying to fill.

What Is Gene Therapy for Overactive Bladder?

Gene therapy for overactive bladder works by introducing a specific gene into the bladder muscle cells. The most studied approach uses a molecule called URO-902, which delivers the gene for the alpha subunit of the BK channel (a large-conductance calcium-activated potassium channel).

In plain language: your bladder muscle cells contain channels that control when the muscle contracts and relaxes. In overactive bladder, these cells fire too easily, causing the muscle to squeeze when it shouldn’t. The BK channel acts like a brake on those contractions. By delivering extra copies of the BK channel gene directly into bladder tissue, the therapy helps muscle cells stay relaxed until you actually need to urinate.

The key difference from other treatments is that gene therapy changes the cells themselves rather than blocking a signal from outside. URO-902 is not a viral gene therapy. It uses a plasmid (a small ring of DNA) as the delivery vehicle, which is generally considered safer than viral vectors because it doesn’t integrate into the patient’s own DNA.

URO-902: The First Clinical Gene Therapy for OAB

URO-902 (also known as pVAX/hSlo) was developed by Urovant Sciences, a subsidiary of Sumitovant Biopharma. It has been tested in both phase 1 and phase 2a clinical trials.

The phase 2a trial (NCT04211831) was a multicentre, randomised, double-blind, placebo-controlled study. Researchers enrolled 80 women aged 40-79 with overactive bladder and urge urinary incontinence who had not responded adequately to standard OAB medications.

Participants were randomly assigned to one of three groups:

URO-902 24mg (26 patients)
URO-902 48mg (27 patients)
Placebo (27 patients)

The treatment was administered as a single intradetrusor injection, meaning the gene therapy was injected directly into the bladder wall muscle using a cystoscope. The procedure was done under local anaesthesia in an outpatient setting, similar to how Botox bladder injections are given.

Key Results: What the Numbers Show

The phase 2a results, published in the Journal of Urology in April 2025 by Enemchukwu and colleagues, showed clear benefits for the higher dose 1.

Urination frequency: Women receiving URO-902 48mg reduced their daily urination episodes by 2.4, compared to just 0.8 in the placebo group (p=0.009). The 24mg dose showed a 2.3 reduction (p=0.017).

Urgency episodes: The 48mg dose significantly reduced daily urgency episodes compared to placebo (p=0.016). This is particularly relevant because urgency is the symptom that most disrupts daily life.

Patient-reported improvement: 58% of women in the 48mg group reported meaningful overall improvement on the Patient Global Impression of Change scale, compared to 31% with placebo (p=0.026).

Incontinence: Both doses showed reductions in urge incontinence episodes, though the differences versus placebo didn’t reach statistical significance in this small study.

The long-term follow-up data showed that improvements in urination frequency, urgency, and incontinence episodes were maintained through 24 weeks for both dose groups. Safety monitoring continued for 48 weeks with no new concerns emerging 3.

My take: these numbers are encouraging for such an early-stage trial. The effect sizes are comparable to what we see with Botox, but from a single treatment using a completely different mechanism. The fact that benefits lasted at least 24 weeks without retreatment is notable.

Safety Profile

Safety was one of the strongest aspects of the trial. Over the full 48 weeks of monitoring:

Treatment-related adverse events occurred at similar rates across all groups, including placebo
The most common side effects were urinary tract infection and temporary haematuria (blood in urine), both likely related to the cystoscopy procedure itself rather than the gene therapy
One patient in the 48mg group developed elevated post-void residual urine volume, which resolved on its own without catheterisation
No patients discontinued the study due to treatment-related adverse events
No serious adverse events were attributed to URO-902

This is a stark contrast to Botox, where urinary retention requiring catheterisation occurs in 5-10% of patients. The safety profile here looks remarkably clean, though the study was small and larger trials will be needed to detect rarer side effects.

EG110A: A Different Approach for Neurogenic Bladder

A separate gene therapy programme is targeting a related problem: neurogenic bladder in people with spinal cord injuries.

EG110A, developed by biotechnology company EG 427, uses a modified herpes simplex virus (non-multiplying) to deliver the gene encoding the active component of botulinum toxin. The virus targets spinal cord nerve cells and essentially turns them into tiny botulinum toxin factories, blocking the sensory signals that cause reflexive bladder spasms.

In March 2025, UTHealth Houston launched a phase Ib/IIa clinical trial of EG110A at four sites across the United States 4. The 52-week trial is enrolling patients aged 18-75 who are at least 12 months post-spinal cord injury.

The potential advantage over standard Botox injections is significant. Spinal cord injury patients currently need roughly 30 Botox injections into the bladder every six months. Preclinical studies suggest that a single dose of EG110A could provide relief lasting several years.

This trial is still in its earliest stages, but it represents a second front in gene therapy for bladder conditions and uses a very different mechanism from URO-902.

How Gene Therapy Compares to Current Treatments

Feature	Anticholinergics	Beta-3 Agonists	Botox Injections	Gene Therapy (URO-902)
How given	Daily pill	Daily pill	Bladder injection every 6-12 months	Single bladder injection
Onset	2-4 weeks	2-4 weeks	1-2 weeks	4-12 weeks
Duration	Ongoing (daily)	Ongoing (daily)	6-12 months	At least 24 weeks (potentially longer)
Retention risk	Low	Low	5-10%	~0% in trial
Cognitive risk	Yes (long-term)	No	No	No
Status	Approved	Approved	Approved	Experimental (phase 2a)

Worth noting: gene therapy for overactive bladder is not trying to replace all existing treatments. It may eventually offer an alternative for the patients who can’t tolerate medications or who find Botox effective but want something longer-lasting.

What Comes Next?

URO-902 has completed phase 2a. The typical path from here would be:

Phase 2b trial — A larger study (probably 200-400 patients) to confirm the right dose and provide stronger efficacy data
Phase 3 trial — A definitive study required for regulatory approval, usually involving hundreds to thousands of patients across multiple countries
Regulatory submission — Filing for approval with the FDA, EMA, and other agencies

Realistically, even with favourable results at each stage, gene therapy for overactive bladder is likely 5-8 years from being available to patients. Drug development timelines are unpredictable, and funding decisions by the sponsoring company will play a major role.

For EG110A, the timeline is even longer since it’s only just entered phase 1b testing.

When to See a Doctor

If you’re living with overactive bladder symptoms that affect your daily life, talk to your GP or a urologist about your current treatment options. Gene therapy is not available outside of clinical trials right now, but several effective treatments exist today.

See a doctor promptly if you experience blood in your urine, pain during urination, or sudden worsening of bladder symptoms. These could indicate a different condition that needs evaluation.

If you’re interested in participating in clinical trials for new overactive bladder treatments, ask your specialist about eligibility or search ClinicalTrials.gov for active studies in your area.

Frequently Asked Questions

What is gene therapy for overactive bladder?

Gene therapy for overactive bladder involves injecting a specially designed DNA molecule directly into the bladder wall. The most studied version, URO-902, delivers a gene that produces potassium channels in bladder muscle cells. These channels help the muscle relax, reducing the involuntary contractions that cause urgency and leakage.

How effective is URO-902 gene therapy for OAB?

In a phase 2a clinical trial, the 48mg dose of URO-902 reduced daily urination episodes by about 2.4 compared to 0.8 for placebo. Urgency episodes also dropped significantly. Around 58% of women in the higher-dose group reported meaningful improvement 1. These results are promising but come from a small study of 80 women.

Is gene therapy for overactive bladder available yet?

No. Gene therapy for overactive bladder is still in clinical trials and not available as a standard treatment. URO-902 completed a phase 2a trial and would need larger phase 2b and phase 3 trials before seeking regulatory approval. Realistically, it could be 5-8 years before a gene therapy for OAB reaches patients.

Is bladder gene therapy safe?

In the URO-902 trial, side effects were similar between the treatment and placebo groups over 48 weeks of safety monitoring. The most common issues were urinary tract infection and temporary blood in the urine, both related to the injection procedure rather than the gene therapy itself. No serious treatment-related adverse events were reported 1.

How does gene therapy compare to Botox for overactive bladder?

Botox injections for OAB need to be repeated every 6-12 months and carry a risk of urinary retention requiring catheterisation. Gene therapy could potentially offer longer-lasting relief from a single treatment because it changes how the bladder muscle cells function at the genetic level. However, gene therapy is still experimental while Botox is an established, approved treatment.

Summary

Gene therapy for overactive bladder represents a genuinely new treatment approach after decades of relying on the same categories of drugs. The URO-902 phase 2a trial showed that a single injection into the bladder wall can reduce urination frequency, urgency, and incontinence with a favourable safety profile. A separate programme, EG110A, is exploring gene therapy for neurogenic bladder in spinal cord injury patients.

These are still early-stage results from small studies. Larger trials are needed, and it will be years before gene therapy for overactive bladder could reach routine clinical practice. But for the millions of people living with OAB who haven’t found adequate relief from existing options, this research offers a reason for cautious optimism.

References

Enemchukwu EA, Kalota S, Robertson K, et al. Gene Therapy With URO-902 (pVAX/hSlo) for the Treatment of Female Patients With Overactive Bladder and Urge Urinary Incontinence: Safety and Efficacy From a Randomized Phase 2a Trial. J Urol. 2025;213(4). PubMed
Chen L, et al. Global Prevalence of Overactive Bladder: A Systematic Review and Meta-analysis. Int Urogynecol J. 2025. PubMed
Peters KM, et al. Long-Term Efficacy and Safety of URO-902 (pVAX/hSlo) in Women With Overactive Bladder and Urge Urinary Incontinence: Final Results of a Phase 2a Trial. J Urol. 2023;209(Suppl 4). Journal of Urology
UTHealth Houston. New clinical trial tests gene therapy vector for overactive bladder in SCI patients. March 2025. UTHealth Houston
Christ GJ, Bhargava S, Bhargava A. Gene Therapy for Overactive Bladder: A Review of BK-Channel α-Subunit Gene Transfer. Curr Bladder Dysfunct Rep. 2021;16:37-44. PMC